Statin induced myotoxicity

European Journal of Internal Medicine

Volumn 23, Issue 4, 2012, Pages 317-324

  Sathasivam, Sivakumar ^a  

^a THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Myalgia; Myopathy; Myositis; Myotoxicity; Rhabdomyolysis; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CALCIUM; CHOLESTEROL; CREATINE KINASE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; SIMVASTATIN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; DRUG MEGADOSE; ELECTROMYOGRAPHY; GENETIC PREDISPOSITION; HUMAN; MUSCLE BIOPSY; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; MYOTOXICITY; NECROTIZING AUTOIMMUNE MYOPATHY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SCREENING TEST; TOXICITY;

EID: 84860532398     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.01.004     Document Type: Short Survey

References (104)

1. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. S. Sathasivam, and B. Lecky Statin induced myopathy BMJ 337 2008 a2286
3. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins Circulation 106 2002 1024 1028
4. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52 60C
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
6. M. Mitka Expanding statin use to help more at-risk patients is causing financial heartburn JAMA 290 2003 2243 2245
7. A. Kashani, C.O. Phillips, J.M. Foody, Y. Wang, S. Mangalmurti, and D.T. Ko Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
8. G.A. Nichols, and C.E. Koro Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 Clin Ther 29 2007 1761 1770
9. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
10. C. Buettner, R.B. Davis, S.G. Leveille, M.A. Mittleman, and K.J. Mukamal Prevalence of musculoskeletal pain and statin use J Gen Intern Med 23 2008 1182 1186
11. Rallidis L, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol in press [Electronic publication ahead of print].
12. P. Grable-Esposito, H.D. Katzberg, S.A. Greenberg, J. Srinivasan, J. Katz, and A.A. Amato Immune-mediated necrotizing myopathy associated with statins Muscle Nerve 41 2010 185 190
13. M. Needham, V. Fabian, W. Knezevic, P. Panegyres, P. Zilko, and F.L. Mastaglia Progressive myopathy with up-regulation of MHC-I associated with statin therapy Neuromuscul Disord 17 2007 194 200
14. M.C. Dalakas Pathophysiology of inflammatory and autoimmune myopathies Presse Med 40 2011 e237 e247
15. L. Christopher-Stine, L.A. Casciola-Rosen, G. Hong, T. Chung, A.M. Corse, and A.L. Mammen A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy Arthritis Rheum 62 2010 2757 2766
16. D.J. Graham, J.A. Staffa, D. Shatin, S.E. Andrade, S.D. Schech, and L. La Grenade Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
17. C. Black, and H. Jick Etiology and frequency of rhabdomyolysis Pharmacotherapy 22 2002 1524 1526
18. K.A. Antons, C.D. Williams, S.K. Baker, and P.S. Phillips Clinical perspectives of statin-induced rhabdomyolysis Am J Med 119 2006 400 409
19. A. Dirks, and K. Jones Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 291 2006 C1208 C1212
20. C. Vaklavas, Y.S. Chatzizisis, A. Ziakas, C. Zamboulis, and G.D. Giannoglou Molecular basis of statin-associated myopathy Atherosclerosis 202 2009 18 28
21. C. Guijarro, L. Blanco-Colio, M. Ortego, C. Alonso, A. Ortiz, and J.J. Plaza 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 83 1998 490 500
22. F. Westwood, A. Bigley, Randall, A.M. Marsden, and R.C. Scott Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity Toxicol Pathol 33 2005 246 257
23. I. Morita, I. Sato, L. Ma, and S. Murato Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin Endothelium 5 1997 107 113
24. O.P. Flint, B.A. Masters, R.E. Gregg, and S.K. Durham Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro Toxicol Appl Pharmacol 145 1997 91 98
25. S.K. Baker Molecular clues into the pathogenesis of statin-mediated muscle toxicity Muscle Nerve 31 2005 572 580
26. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237
27. Y.S. Chatzizisis, C. Vaklavas, and G.D. Giannoglou Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy? Am J Cardiol 101 2008 1071
28. H. Paiva, K.M. Thelen, R. Van Coster, J. Smet, B. De Paepe, and K.M. Mattila High-dose statins and skeletal muscle metabolism in humans: a randomized controlled trial Clin Pharmacol Ther 78 2005 60 68
29. C.F. Schaars, and A.F. Stalenhoef Effects of ubiquinone (coenzyme Q10) on myopathy in statin users Curr Opin Lipidol 19 2008 553 557
30. M.G. Mohaupt, R.H. Karas, E.B. Babiychuk, V. Sanchez-Freire, K. Monastyrskaya, and L. Iyer Association between statin-associated myopathy and skeletal muscle damage CMAJ 181 2009 E11 E18
31. P.P. Toth, C.R. Harper, and T.A. Jacobson Clinical characterization and molecular mechanisms of statin myopathy Expert Rev Cardiovasc Ther 6 2008 955 969
32. T.A. Abd, and T.A. Jacobson Statin-induced myopathy: a review and update Expert Opin Drug Saf 10 2011 373 387
33. S. Ahmad Lovastatin induced lupus erythematosus Arch Intern Med 151 1991 1667 1668
34. N. Giordano, M. Senesi, G. Mattii, E. Battisti, M. Villanova, and C. Gennari Polymyositis associated with simvastatin Lancet 349 1997 1600 1601
35. B. Parmar, P. Francis, and N.K. Ragge Statins, fibrates, and ocular myasthenia Lancet 360 2002 717
36. F. Mach Statins as immunomodulatory agents Circulation 109 2004 II15 II17
37. B. Kwak, F. Mulhaupt, and F. Mach Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins Autoimmun Rev 2 2003 332 338
38. A.L. Mammen, T. Chung, L. Christopher-Stine, P. Rosen, A. Rosen, and K.R. Doering Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy Arthritis Rheum 63 2011 713 721
39. C. Martini, L. Trapani, L. Narciso, M. Marino, A. Trentalance, and V. Pallottini 3-Hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation J Cell Physiol 220 2009 524 530
40. F.L. Mastaglia, and M. Needham Update on toxic myopathies Curr Neurol Neurosci Rep 12 2011 54 61
41. C. Liang, and M. Needham Necrotizing autoimmune myopathy Curr Opin Rheumatol 23 2011 612 619
42. Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care Res (Hoboken) in press [Electronic publication ahead of print].
43. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins Stroke 33 2002 2337 2341
44. R.S. Rosenson Current overview of statin-induced myopathy Am J Med 116 2004 408 416
45. M.H. Davidson, and J.G. Robinson Safety of aggressive lipid management J Am Coll Cardiol 49 2007 1753 1762
46. A. Kulik, and M. Ruel Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety Expert Opin Drug Saf 8 2009 559 571
47. H. Desai, W.S. Aronow, C. Ahn, K. Gandhi, H. Amin, and H.M. Lai Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins Arch Gerontol Geriatr 51 2010 149 151
48. D. Poldermans Statins and noncardiac surgery: current evidence and practical considerations Cleve Clin J Med 76 2009 S79 S83
49. G.D. Vladutiu, Z. Simmons, P.J. Isackson, M. Tarnopolsky, W.L. Peltier, and A.C. Barboi Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34 2006 153 162
50. P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, and B.J. Kimura Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
51. L. Sailler, C. Pereira, A. Bagheri, E. Uro-Coste, B. Roussel, and D. Adoue Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study Ann Rheum Dis 67 2008 614 619
52. M.K. Pasanen, H. Fredrikson, P.J. Neuvonen, and M. Niemi Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 82 2007 726 733
53. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2009 130 133
54. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, and F. Matsuda SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
55. D. Voora, S.H. Shah, I. Spasojevic, S. Ali, C.R. Reed, and B.A. Salisbury The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
56. A. Ghatak, O. Faheem, and P.D. Thompson The genetics of statin-induced myopathy Atherosclerosis 210 2010 337 343
57. P. Zuccaro, G. Mombelli, L. Calabresi, D. Baldasarre, I. Palmi, and C.R. Sirtori Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin Pharmacol Res 55 2007 310 317
58. J. Oh, M.R. Ban, B.A. Miskie, R.L. Pollex, and R.A. Hegele Genetic determinants of statin intolerance Lipids Health Dis 6 2007 7
59. L. Puccetti, F. Ciani, and A. Auteri Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study Atherosclerosis 211 2010 28 29
60. G. Ruano, P.D. Thompson, A. Windemuth, R.L. Seip, A. Dande, and A. Sorokin Physiogenomic association of statin-related myalgia to serotonin receptors Muscle Nerve 36 2007 329 335
61. P.J. Isackson, H.M. Ochs-Balcom, C. Ma, J.B. Harley, W. Peltier, and M. Tarnopolsky Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional function of EYS Muscle Nerve 44 2011 531 538
62. A. Gupta, and P.D. Thompson The relationship of vitamin D deficiency to statin myopathy Atherosclerosis 215 2011 23 29
63. P. Lee, J.R. Greenfield, and L.V. Campbell Vitamin D deficiency - a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf) 71 2009 154 155
64. W. Ahmed, N. Khan, C.J. Glueck, S. Pandey, P. Wang, and N. Goldenberg Low serum 25 (OH) vitamin levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Transl Res 153 2009 11 16
65. C.J. Glueck, S.B. Budhani, S.S. Masineni, C. Abuchaibe, N. Khan, and P. Wang Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance Curr Med Res Opin 27 2011 1683 1690
66. B. Nier, P.D. Weinberg, G. Rimbach, E. Stocklin, and L. Barella Differential gene expression in skeletal muscle of rats with vitamin E deficiency IUBMB Life 58 2006 540 548
67. F. Galli, and L. Iuliano Do statins cause myopathy by lowering vitamin E levels? Med Hypotheses 74 2010 707 709
68. M.A. Silva, A.C. Sawnson, P.J. Gandhi, and G.R. Tataronis Statin-related adverse events: a meta-analysis Clin Ther 28 2006 26 35
69. R.W. Kuncl Agents and mechanisms of toxic myopathy Curr Opin Neurol 22 2009 506 515
70. J. Sidaway, Y. Wang, A.M. Marsden, T.C. Orton, F.R. Westwood, and C.T. Azuma Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy Xenobiotica 39 2009 90 98
71. M. Silva, M.L. Matthews, C. Jarvis, N.M. Nolan, P. Belliveau, and M. Malloy Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy Clin Ther 29 2007 253 260
72. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581
73. G.M. Ray Antiretroviral and statin drug-drug interactions Cardiol Rev 17 2009 44 47
74. M. Bottorff Statin safety and drug interactions: clinical implications Am J Cardiol 97 2006 S27 S31
75. A. Corsini, and R. Ceska Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles heel? Curr Med Res Opin 27 2011 1551 1562
76. T. Prueksaritanont, K.M. Richards, Y. Qiu, K. Strong-Basalyga, A. Miller, and C. Li Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes Pharm Res 22 2005 71 78
77. R. Nakagomi-Hagihara, D. Nakai, and T. Tokui Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans Xenobiotica 37 2007 416 426
78. D.W. Schneck, B.K. Birmingham, J.A. Zalikowski, P.D. Mitchell, Y. Wang, and P.D. Martin The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 75 2004 455 463
79. A. Corsini, and S. Bellosta Drug-drug interaction with statins Expert Rev Clin Pharmacol 1 2008 105 113
80. P. Jones, and M. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol 95 2005 120 122
81. Merck and Company ZOCOR prescribing information 2011 Whitehouse station New Jersey, USA
82. M.H. Davidson, D. Maccubbin, M. Stepanavage, J. Strony, and T. Musliner Striated muscle safety of ezetimibe/simvastatin (Vytorin) Am J Cardiol 97 2006 223 228
83. A. Kashani, T. Sallam, S. Bheemreddy, D.L. Mann, Y. Wang, and J.M. Foody Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials Am J Cardiol 101 2008 1606 1613
84. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton National Lipid Association Statin Safety Assessment Task Force: final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
85. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 260 2002 7 22
86. H.Y. Meltzer, and P.A. Holy Black-white differences in serum creatine phosphokinase (CPK) activity Clin Chim Acta 54 1974 215 224
87. L.P. Rowland, J. Willner, S. DiMauro, and A. Miranda Approaches to the membrane theory of Duchenne muscular dystrophy C. Angelini, G.A. Danieli, D. Fontanari, Muscular dystrophy - advances and new trends 1980 Excerpta Medica Amsterdam 3 13
88. P. Brancaccio, N. Maffulli, and F.M. Limongelli Creatine kinase monitoring in sport medicine Br Med Bull 81-2 2007 209 230
89. C.J. Glueck, B. Rawal, N.A. Khan, S. Yeramaneni, N. Goldenberg, and P. Wang Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 58 2009 233 238
90. T. Jacobson Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia Mayo Clin Proc 83 2008 687 700
91. G. Fernandez, E.S. Spatz, C. Jablecki, and P.S. Phillips Statin myopathy: a common dilemma not reflected in clinical trials Cleve Clin J Med 78 2011 393 403
92. R.H. Eckel Approach to the patient who is intolerant of statin therapy J Clin Endocrinol Metab 95 2010 2015 2022
93. P.D. Thompson, P.M. Clarkson, and R.S. Rosenson National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
94. K.A. Radcliffe, and W.W. Campbell Statin myopathy Curr Neurol Neurosci Rep 8 2008 66 72
95. A. Draeger, K. Monastyrskaya, M. Mohaupt, H. Hoppeler, H. Savolainen, and C. Allemann Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 210 2006 94 102
96. I.M. Bronner, J.E. Hoogendijk, A.R. Wintzen, M.F. van der Meulen, W.H. Linssen, and J.H. Wokke Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy J Neurol 250 2003 480 485
97. P.S. Phillips Ezetimibe and statin-associated myopathy Ann Intern Med 141 2004 649
98. P.P. Toth Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs Drugs 70 2010 1363 1379
99. C.F. Huang, T.C. Li, C.C. Lin, C.S. Liu, H.C. Shih, and M.M. Lai Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients Eur J Cardiovasc Prev Rehabil 14 2007 438 440
100. D.J. Becker, R.Y. Gordon, S.C. Halbert, B. French, P.B. Morris, and D.J. Rader Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 150 2009 W147 W149
101. S.K. Baker, and I.A. Samjoo A neuromuscular approach to statin-related myotoxicity Can J Neurol Sci 35 2008 8 21
102. J.M. Young, C.M. Florkowski, S.L. Molyneux, R.G. McEwan, C.M. Frampton, and P.M. George Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia Am J Cardiol 100 2007 1400 1403
103. G. Caso, P. Kelly, M.A. McNurlan, and W.E. Lawson Effect of coenzyme q10 on myopathic symptoms in patients treated with statins Am J Cardiol 99 2007 1409 1412
104. M.C. Dalakas Immunotherapy of inflammatory myopathies: practical approach and future prospects Curr Treat Options Neurol 13 2011 311 323